Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM
Sagar Lonial(Emory University), Jesus Bardeja(Sarah Cannon), Prasoon Chaturvedi(C4 Therapeutics (United States)), Urvi A. Shah(United States Fish and Wildlife Service), Bradley Class(National Institutes of Health), Adam Crystal(C4 Therapeutics (United States)), Shambavi Richard(Medical Oncology Hematology Consultants), Paul G. Richardson(Harvard University), Michelle Mahler(C4 Therapeutics (United States)), Sikander Ailawadhi(Jacksonville College), Manisha Bhutani(Carolinas Healthcare System), Stewart L. Fisher(C4 Therapeutics (United States)), Jason K. Kirby(TU Bergakademie Freiberg), Neha Mehta-Shah(Washington University in St. Louis), Andrew J. Yee(Harvard University), Thomas G. Martin(University of California San Francisco Medical Center), Eli Muchtar(Mayo Clinic), Oliver Schönborn‐Kellenberger(C4 Therapeutics (United States)), Matthew Schnaderbeck(C4 Therapeutics (United States)), Amanda Hoerres(C4 Therapeutics (United States)), Roman V. Agafonov(C4 Therapeutics (United States)), Michael R. Palmer(C4 Therapeutics (United States)), Samantha Perino(Enveda Therapeutics (United States)), Roy M. Pollock(C4 Therapeutics (United States)), Jeffrey Matous(Colorado Blood Cancer Institute), Cathleen Gorman(C4 Therapeutics (United States))
Cited by 11
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k